What it is
KPV is a tripeptide fragment from alpha-MSH studied for inflammation and barrier repair.
Evidence boundary
Preclinical / limited human evidence.
Trial evidence
- PMID 41241376 — Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.
- PMID 41209547 — Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.
- PMID 40073467 — Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.
- PMID 28343991 — Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Week 1 (titration) | 200 mcg | 4 U (0.04 mL) | Once or twice daily | 1.4–2.8 mg/week |
| Week 2 | 300 mcg | 6 U (0.06 mL) | Once or twice daily | 2.1–4.2 mg/week |
| Week 3 | 400 mcg | 8 U (0.08 mL) | Once or twice daily | 2.8–5.6 mg/week |
| Weeks 4–8 (target) | 500 mcg | 10 U (0.1 mL) | Once or twice daily | 3.5–7 mg/week |
Week 1 (titration)
- Dose
- 200 mcg
- Draw / measure
- 4 U (0.04 mL)
- Frequency
- Once or twice daily
- Weekly total
- 1.4–2.8 mg/week
Week 2
- Dose
- 300 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Once or twice daily
- Weekly total
- 2.1–4.2 mg/week
Week 3
- Dose
- 400 mcg
- Draw / measure
- 8 U (0.08 mL)
- Frequency
- Once or twice daily
- Weekly total
- 2.8–5.6 mg/week
Weeks 4–8 (target)
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once or twice daily
- Weekly total
- 3.5–7 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Light (250 mcg/day): Daily anti-inflammatory maintenance.
-
Standard (500 mcg/day): Common research dose.
-
Higher (1 mg/day): IBD or acute inflammation protocols.
-
Cycle: 8–12 weeks active dosing, then reassess. Continuous use is acceptable given safety profile.
-
Inflammation response
-
Tolerability
-
Injection-site reactions
Practical rules
- Rotate sites if it is being compared in notes.
- Don’t oversell the gut or skin claim.
Related protocols
BPC-157 Peptide Protocol & DosingLL-37 Peptide Protocol & DosingARA-290 Peptide Protocol & DosingGHK-Cu Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for KPV Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes